Hypertension, a major metabolic syndrome condition, has experienced a rapid increase in global prevalence. AGT (angiotensinogen), the key precursor in the RAAS pathway, serves as a prime target for RNAi therapies. GemPharmatech has developed an AGT humanized mouse model to advance hypertension research and developed a modified human RENIN virus to induce sustained high blood pressure in these mice—a critical step for preclinical evaluation.